Business
ParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicines
SAN FRANCISCO, May 07, 2026--ParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicines
About this update from Metaplanet Inc.
[{"type":"image","alt":"From left to right: ParcelBio co-founders Chris Carlson, Ph.D., Chief Scientific Officer and David Weinberg, Ph.D., Chief Executive Officer (Photo credit: Erin Beach / ParcelBio)","displaySize":"","headline":null,"caption":"From left to right: ParcelBio co-founders Chris Carlson, Ph.D., Chief Scientific Officer and David Weinberg, Ph.D., Chief Executive Officer (Photo credit: Erin Beach / ParcelBio)","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/f0257dc1cfb1b399735f7e91b1cc30b8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7LBafhCZPZRrXRW4nlcxQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/f0257dc1cfb1b399735f7e91b1cc30b8","width":480,"height":320},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/78FVDCNrSidmaiP4dvOUBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTQyNw--/https://media.zenfs.com/en/business-wire.com/f0257dc1cfb1b399735f7e91b1cc30b8","width":480,"height":320}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/4412bb7d103d82626615b0a6cc5783b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3VHtEd4LH.CdWKV3vgOEDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/4412bb7d103d82626615b0a6cc5783b2","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fL0yuuciPk3KuB7mi.mO.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/4412bb7d103d82626615b0a6cc5783b2","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SGh5kn9pT8G4hxy5SwaIRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/4412bb7d103d82626615b0a6cc5783b2","width":1024,"height":512}}},{"type":"list","items":[{"val":[{"type":"text","content":"Financing led by Breyer Capital with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and other investors","length":148,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Proceeds will advance APEXm™ platform and in vivo CAR-T programs for autoimmune disease","length...